Tiotropium in asthma: what is the evidence and how does it fit in?

by David M.G. Halpin
Published 2016-01-01

Inhalation Devices

by Petra Moroni-Zentgraf, Omar S. Usmani, David M. G. Halpin
Published 2018-01-01

Distribution, Temporal Stability and Appropriateness of Therapy of Patients With COPD in the UK in Relation to GOLD 2019

by David M.G. Halpin, Hilda J.I. de Jong, Victoria Carter, Derek Skinner, David Price
Published 2019-09-01

Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials

by David M.G. Halpin, Claus F. Vogelmeier, Karen Mezzi, Pritam Gupta, Konstantinos Kostikas, Jadwiga A. Wedzicha
Published 2021-02-01

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial

by Donald P. Tashkin, Marc Miravitlles, Bartolomé R. Celli, Norbert Metzdorf, Achim Mueller, David M. G. Halpin, Antonio Anzueto
Published 2018-10-01

Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial

by Klaus F. Rabe, David M. G. Halpin, MeiLan K. Han, Marc Miravitlles, Dave Singh, Lars Grönke, Florian Voß, Fernando J. Martinez
Published 2020-07-01

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design

by Sally Worsley, Neil Snowise, David M.G. Halpin, Dawn Midwinter, Afisi S. Ismaila, Elaine Irving, Leah Sansbury, Maggie Tabberer, David Leather, Chris Compton
Published 2019-11-01

Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1

by David M. G. Halpin, Eli O. Meltzer, Wendelgard Pisternick-Ruf, Petra Moroni-Zentgraf, Michael Engel, Liliana Zaremba-Pechmann, Thomas Casale, J. Mark FitzGerald
Published 2019-07-01

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses

by David M.G. Halpin, Ruby Birk, Noushin Brealey, Gerard J. Criner, Mark T. Dransfield, Emma Hilton, David A. Lomas, Chang-Qing Zhu, David A. Lipson
Published 2018-05-01

Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis

by David M. G. Halpin, Eckard H. Hamelmann, Peter A. Frith, Petra M. Moroni-Zentgraf, Benjamin van Hecke, Anna Unseld, Huib A. M. Kerstjens, Stanley J. Szefler
Published 2020-03-01

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

by David B. Price, Sinthia Bosnic-Anticevich, Ian D. Pavord, Nicolas Roche, David M. G. Halpin, Leif Bjermer, Omar S. Usmani, Guy Brusselle, Simon Wan Yau Ming, Sarang Rastogi
Published 2019-08-01

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice

by David M.G. Halpin, Sally Worsley, Afisi S. Ismaila, Kai-Michael Beeh, Dawn Midwinter, Janwillem W.H. Kocks, Elaine Irving, Jose M. Marin, Neil Martin, Maggie Tabberer, Neil G. Snowise, Chris Compton
Published 2021-06-01

Blood eosinophil count predicts treatment failure and hospital readmission for COPD

by Marjan Kerkhof, Isha Chaudhry, Ian D. Pavord, Marc Miravitlles, Chin Kook Rhee, David M.G. Halpin, Omar S. Usmani, Rupert Jones, Janwillem Kocks, Marianna Alacqua, Tamsin Morris, Alan Kaplan, David B. Price
Published 2020-11-01

InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations

by Dave Singh, Gerard J. Criner, Mark T. Dransfield, David M. G. Halpin, MeiLan K. Han, Peter Lange, Sally Lettis, David A. Lipson, David Mannino, Neil Martin, Fernando J. Martinez, Bruce E. Miller, Robert Wise, Chang-Qing Zhu, David Lomas
Published 2021-04-01

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis

by MeiLan K. Han, Gerard J. Criner, Mark T. Dransfield, David M.G. Halpin, Christine E. Jones, Sally Kilbride, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Neil Martin, Fernando J. Martinez, Robert A. Wise, Ian P. Naya, Dave Singh
Published 2021-03-01

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardio...

by Nicola C. Day, Subramanya Kumar, Gerard Criner, Mark Dransfield, David M. G. Halpin, MeiLan K. Han, C. Elaine Jones, Morrys C. Kaisermann, Sally Kilbride, Peter Lange, David A. Lomas, Neil Martin, Fernando J. Martinez, Dave Singh, Robert Wise, David A. Lipson
Published 2020-06-01